---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Place in treatment, anticipated use, and care setting. Topics: VA/DoD 2025 Recommendation 24 against atomoxetine or atomoxetine plus oxybutynin; VA/DoD 2025 guideline: evidence review period and research need, predating AD109 phase 3 results; VA/DoD 2025 treatment sequence and referral to a sleep medicine specialist; Manufacturer positioning: launch focus, then adjunctive and first-line use; 4 further topics. 9 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

- Guideline sequencing: the VA/DoD 2025 algorithm prescribes PAP as first-line therapy for severe OSA (AHI above 30 events per hour) and PAP or a mandibular advancement device for an AHI of 5 to below 30, and refers patients who do not adopt or use PAP or a mandibular advancement device to a sleep medicine specialist. The ACP recommends CPAP as initial therapy (strong recommendation, moderate-quality evidence) and mandibular advancement devices as an alternative (weak recommendation, low-quality evidence). The AASM and AADSM recommend that sleep physicians consider oral appliances for adults intolerant of CPAP therapy or preferring alternate therapy. After PAP is unsuccessful or not accepted, guidelines suggest referral for hypoglossal nerve stimulation evaluation when the AHI is 15 or more per hour (VA/DoD) and recommend discussing referral to a sleep surgeon when the BMI is below 40 kg/m2 or to a bariatric surgeon when the BMI is 35 kg/m2 or more (AASM). Wake-promoting agents are suggested for residual excessive daytime sleepiness in patients optimally treated with sufficient therapy use (VA/DoD).
- VA/DoD 2025 Recommendation 24 suggests against atomoxetine or a combination of atomoxetine and oxybutynin for OSA (“Weak against”). It rests on 2 randomized trials with mixed results, low confidence in the evidence, and known harms (atomoxetine may increase blood pressure; oxybutynin's anticholinergic effects can increase the risk of falls and cause cognitive impairment). The guideline notes that aroxybutynin is not approved by the FDA. Its evidence review ended on March 31, 2024, and it states that randomized trials of these agents as salvage or adjunctive therapy are needed; Apnimed states that both AD109 phase 3 trials, SynAIRgy and LunAIRo, were completed in 2025.
- AD109 phase 3 population: SynAIRgy and LunAIRo enrolled adults with mild to severe OSA who were intolerant of or refused PAP. PAP failure was defined as no PAP use for at least 3 months before randomization or return or removal of the device, and PAP refusal as refusal of PAP after a positive sleep study or refusal of a recommended sleep study due to unwillingness to consider PAP. In the SynAIRgy intent-to-treat set of 615 participants, 411 (66.8%) had PAP intolerance and 205 (33.3%) PAP refusal.
- Apnimed's stated positioning: the initial launch would focus on the approximately 10.5 million people in the United States diagnosed with OSA but untreated (from a 2025 National Sleep Foundation survey), then on patients using another treatment whose OSA is not fully resolved (as a complement to PAP or GLP-1 therapies), with first-line use as the long-term target. The company presentation describes the target patient as intolerant to PAP (refused or failed), diagnosed within the past 2 years, and without insomnia or active cardiovascular disease. Apnimed plans 125 to 150 field representatives covering 15,000 to 20,000 sleep specialists and high-volume primary care practices. Company-cited surveys report that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it (Wells Fargo, August 2025) and that approximately 80% of 1,500 surveyed patients reported likelihood of asking their healthcare provider to try a nightly pill proven to improve OSA (SHINE Survey).
- An editorial on SynAIRgy describes AD109 as a likely addition to a multimodal treatment framework, particularly for patients unable or unwilling to use PAP.

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf); [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/); [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/); [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/); [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/); [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/); [ClinicalTrials.gov NCT05811247](https://clinicaltrials.gov/study/NCT05811247); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177); [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-2.2.2.2-2"></a>

### VA/DoD 2025 Recommendation 24 against atomoxetine or atomoxetine plus oxybutynin

> “For treatment of obstructive sleep apnea, we suggest against atomoxetine or a combination of atomoxetine and oxybutynin. (Weak against | Reviewed, New-added)”
> “Evidence from 2 RCTs (203,204) provided mixed results on whether atomoxetine or the combination of atomoxetine and oxybutynin improve critical outcomes of obstructive sleep apnea (OSA) such as reductions in apnea hypopnea index (AHI), improvements in daytime functioning, or sleep-related quality of life (QoL).”
> “The combination of atomoxetine and aroxybutynin showed a reduction in AHI, daytime fatigue, and respiratory arousal. Aroxybutynin, the R-enantiomer of oxybutynin, is not approved by the FDA and not commercially available.”
> “Confidence in the quality of overall evidence was rated as low due to small sample sizes and the risk for imprecision. A weak against recommendation for atomoxetine and the combination of atomoxetine and oxybutynin was made because of known harms from these medications, inconclusive evidence that they are effective in OSA, and the low quality of evidence.”
> “Specifically, atomoxetine may increase blood pressure and exacerbate cardiovascular disorders and oxybutynin’s anticholinergic effects can increase risk for falls and cause cognitive impairment.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.2-3"></a>

### VA/DoD 2025 guideline: evidence review period and research need, predating AD109 phase 3 results

> “Based on evidence reviewed through March 31, 2024”
> “Randomized control trials (RCTs) or SRs of RCTs published on or after May 15, 2018, to March 31, 2024.”
> “RCTs of atomoxetine and combination of atomoxetine and oxybutynin as a salvage or adjunctive therapy for OSA are needed.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.2-4"></a>

### VA/DoD 2025 treatment sequence and referral to a sleep medicine specialist

> “Prescribe PAP as first line therapy for patient with severe OSA (i.e., AHI >30 events per hour)”
> “Prescribe PAP or MAD for other OSA severity (i.e., AHI 5 to <30 events per hour), based on clinical evaluation, comorbidities, and patient preference.”
> “Refer patients for follow up to a sleep medicine specialist:”
> “Who do not adopt/use PAP and/or MAD therapy”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.2-5"></a>

### Manufacturer positioning: launch focus, then adjunctive and first-line use

> “We intend to focus our initial launch phase of Oxnimbi, if approved, on the approximately 10.5 million people in the United States who are diagnosed with OSA but untreated, estimated based on the results of a survey conducted by the National Sleep Foundation in 2025”
> “Thereafter, we intend to focus on patients using another treatment who have not fully resolved their OSA, for example, providing Oxnimbi as a compliment to PAP or GLP-1s. Our long-term target market is patients seeking initial treatment, with Oxnimbi as a first-line solution, and analogs suggest that oral therapies are likely to evolve into first-line treatments over time.”
> “Given its direct and distinct mechanism, we believe Oxnimbi, if approved, could be used as a potential complement to PAP and GLP-1 therapies in obese patients with moderate-to-severe OSA, in addition to serving the full spectrum of OSA patients, including those who are not obese.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.2-6"></a>

### Manufacturer description of the target patient

> “We believe that the target patient is readily identifiable, aligns with clinical intuition, and can offer the highest probability of treatment success and positive feedback”
> “Intolerant to PAP (refused or failed)”
> “Unencumbered absence of insomnia, and active CV disease”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-2.2.2.2-7"></a>

### Manufacturer-cited surveys of anticipated prescribing and patient demand

> “A Wells Fargo survey conducted in August of 2025 reported that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it, if approved, either as a first-line therapy, after PAP or together with PAP”
> “Market research conducted by us reported that surveyed healthcare providers believe Oxnimbi, based on its product profile description, could help reengage approximately 50% of their diagnosed but untreated patients.”
> “The SHINE Survey indicated that of the 1,500 patients surveyed, approximately 80% reported likelihood of asking their healthcare provider to try a nightly pill proven to improve OSA, defined as an AHI reduction of 50%.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.2-8"></a>

### Care setting: sleep specialists and primary care, manufacturer statement

> “The legacy, PAP machine-dominant, OSA treatment paradigm has been concentrated primarily in sleep specialists.”
> “We expect to deploy a targeted field sales organization of 125 to 150 representatives focused initially on covering 15,000 to 20,000 sleep specialists and high-volume primary care practices that manage patients with OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.2-9"></a>

### Place in a multimodal treatment framework in an editorial on SynAIRgy

> “AD109 may not replace established therapies such as PAP, but it more likely represents a useful addition to a multimodal treatment framework, particularly for patients who are unable or unwilling to use PAP therapy.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
